Astellas invests $50 million in Taysha Gene Therapies
Taysha will license AAV gene therapy candidates TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy to Astellas.
List view / Grid view
Taysha will license AAV gene therapy candidates TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy to Astellas.
Researchers describe how a new drug is able to reduce the symptoms and activate the dormant neurons characteristic of Rett Syndrome...
18 May 2016 | By Mandy Parrett, Editorial Assistant
Biopharmaceutical company, Newron, has announced that its Investigational New Drug (IND) application to evaluate Sarizotan in treatment of Rett Syndrome has been approved by the FDA.